A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2017
At a glance
- Drugs KBP 5074 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 07 Jun 2017 Biomarkers information updated
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.